Prestige Consumer Healthcare Inc. reported its second‑quarter and first‑half fiscal 2026 results on November 6, 2025. Revenue for the quarter fell 3.4% year‑over‑year to $274.1 million, while net income was $42.2 million and diluted earnings per share were $0.86. Non‑GAAP adjusted net income rose to $52.5 million and adjusted diluted EPS to $1.07. For the first six months, revenue was $523.6 million, down 5.0% YoY, with net income of $89.7 million and diluted EPS of $1.81; non‑GAAP adjusted figures were $99.9 million and $2.02, respectively.
The company’s North American OTC Healthcare segment saw a 3.4% decline in quarter revenue, largely due to limited supply of its flagship Clear Eyes eye‑care product. International OTC sales were largely flat, and e‑commerce consumption continued to grow double‑digit year‑over‑year, underscoring the strength of the company’s online channel. The results also highlighted ongoing supply‑chain challenges that the company is addressing through the pending acquisition of Pillar5 Pharma and the addition of two new third‑party suppliers.
Looking ahead, Prestige reiterated its fiscal 2026 net‑sales outlook and expects eye‑care supply to improve in the second half of the year as the Pillar5 transaction closes. The company projects free cash flow of $245 million or more and has already repurchased 1.1 million shares at a cost of $75 million in the quarter. Net debt remains at approximately $900 million, giving the company a leverage ratio of 2.4× and ample flexibility for future capital deployment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.